ReviewFrontiers in microbiology2019
Genetic Engineering of Bacteriophages Against Infectious Diseases.
Review in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 171 citations in OpenAlex.
- Genetic engineering of cyanophages for harmful cyanobacterial bloom treatment-A mini review.Synthetic and systems biotechnology · 2027Review
- Genetic Exchanges Shape the Evolutionary Diversification Among Shigella phages.Journal of molecular evolution · 2026Article
- Phage as control strategy against the foodborne pathogen, Bacillus cereus.Archives of microbiology · 2026Review
- A fully synthetic Golden Gate assembly system for engineering aProceedings of the National Academy of Sciences of the United States of America · 2026Article
- A review on phytochemical and bacteriophage based therapeutic strategies for the management of Brucellosis.Frontiers in veterinary science · 2026Review
- Microbiome and plant relationship: a symbiosis against phytopathogens.Frontiers in plant science · 2026Review
- From Isolation to Application: Designing a Multi-Target Phage Cocktail for Bivalve Safety.Microorganisms · 2025Article
- Bioinformatic Identification of CRISPR-Cas Systems inPathogens (Basel, Switzerland) · 2025Article
- CRISPR-Cas10-Assisted Structural Modification of StaphylococcalACS synthetic biology · 2025Article
- Review
- Broad host range phage LPC-1 reduce the risk of Listeria monocytogenes contamination in different food matrices.Archives of microbiology · 2025Article
- Bacteriophages as Targeted Therapeutic Vehicles: Challenges and Opportunities.Bioengineering (Basel, Switzerland) · 2025Review
- Engineering bacteriophages for targeted superbug eradication.Molecular biology reports · 2025Review
- Evaluation of host immune responses to Mycobacteriophage Fionnbharth by route of delivery.Virology journal · 2025Article
- The application of bacteriophage to veterinary and One-Health medicine-a road map.Frontiers in microbiology · 2025Review
- Engineered Bacteriophages: Advances in Phage Genome Redesign Strategies for Therapeutic and Environmental Applications.Protein and peptide letters · 2025Review
- Emerging challenges in aquaculture: Current perspectives and human health implications.Veterinary world · 2025Review
- Protocol for establishing CRISPR-Cas12a for efficient genome editing of Pseudomonas aeruginosa phages.STAR protocols · 2024Article
- Overview of Phage Defense Systems in Bacteria and Their Applications.International journal of molecular sciences · 2024Review
- Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections.Infectious disease reports · 2024Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Bacteriophages (phages) are the most abundant and widely distributed organisms on Earth, constituting a virtually unlimited resource to explore the development of biomedical therapies. The therapeutic use of phages to treat bacterial infections ("phage therapy") was conceived by Felix d'Herelle nearly a century ago. However, its power has been realized only recently, largely due to the emergence of multi-antibiotic resistant bacterial pathogens. Progress in technologies, such as high-throughput sequencing, genome editing, and synthetic biology, further opened doors to explore this vast treasure trove. Here, we review some of the emerging themes on the use of phages against infectious diseases. In addition to phage therapy, phages have also been developed as vaccine platforms to deliver antigens as part of virus-like nanoparticles that can stimulate immune responses and prevent pathogen infections. Phage engineering promises to generate phage variants with unique properties for prophylactic and therapeutic applications. These approaches have created momentum to accelerate basic as well as translational phage research and potential development of therapeutics in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.